Astellas Pharma Inc: Leukemia trials

The registry lists 16 Leukemia studies with Astellas Pharma Inc as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 8Phase 2 6Phase 3 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)CompletedNCT04079296Phase 1/2Results posted
• A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)CompletedNCT03730012Phase 1/2Results posted
• A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)CompletedNCT02997202Phase 3Results posted
• A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete RemissionCompletedNCT02927262Phase 2Results posted
• Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02014558Phase 1/2Results posted
• Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)No longer availableNCT03409081
• Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)Approved for marketingNCT03070093
• Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart ReviewCompletedNCT03047083
• A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT02864290Phase 1
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)TerminatedNCT02610062Phase 1
• A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02236013Phase 1
• Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02181660Phase 1
• Ribomustin in the First Line Therapy of Chronic Lymphocytic LeukemiaCompletedNCT02110394
• Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)CompletedNCT00285259Phase 2
• A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00073489Phase 2
• Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic LeukemiaCompletedNCT00036257Phase 1